Newly activated UI Cancer Center Clinical Trials

The following study has recently been activated for patient enrollment by the University of Illinois Cancer Center Clinical Trials Office (CTO). Please click on the link to learn about the details regarding the study on For more information or questions about a study, please email or call 312-355-5112.

MEK-NF-201: a Phase 2b Trial of the MEK ½ Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients with Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) that are Causing Significant Morbidity

Sponsor: SpringWorks Therapeutics, Inc.
Principal Investigator: Stefania Maraka, MD

This trial is for English-speaking patients only.

Translate »